AbCellera Biologics Inc
General ticker "ABCL" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $851.8M
AbCellera Biologics Inc does not follow the US Stock Market performance with the rate: -29.8%.
Estimated limits based on current volatility of 3.5%: low 2.65$, high 2.84$
Factors to consider:
- Current price 12.8% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [3.27$, 7.47$]
- 2024-12-30 to 2025-12-30 estimated range: [2.99$, 6.92$]
Financial Metrics affecting the ABCL estimates:
- Negative: Non-GAAP EPS, $ of -0.52 <= 0.10
- Negative: Operating profit margin, % of -86.18 <= 1.03
- Negative: Operating cash flow per share per price, % of -2.91 <= 2.35
- Negative: Industry operating cash flow per share per price (median), % of 0.50 <= 3.85
- Positive: -0.96 < Investing cash flow per share, $ of -0.76
- Negative: negative Net income
Short-term ABCL quotes
Long-term ABCL plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $375.20MM | $485.42MM | $38.02MM |
| Operating Expenses | $170.79MM | $268.91MM | $275.23MM |
| Operating Income | $204.41MM | $216.51MM | $-237.21MM |
| Non-Operating Income | $14.74MM | $22.59MM | $63.18MM |
| Interest Expense | $5.22MM | $4.04MM | $0.00MM |
| R&D Expense | $62.06MM | $107.88MM | $175.66MM |
| Income(Loss) | $219.15MM | $239.10MM | $-174.03MM |
| Taxes | $65.69MM | $80.58MM | $-27.63MM |
| Profit(Loss) | $153.46MM | $158.52MM | $-146.40MM |
| Stockholders Equity | $1,025.73MM | $1,233.28MM | $1,152.32MM |
| Inventory | $1.67MM | $1.53MM | $1.11MM |
| Assets | $1,318.57MM | $1,540.91MM | $1,488.09MM |
| Operating Cash Flow | $244.58MM | $277.36MM | $-43.88MM |
| Capital expenditure | $58.45MM | $72.66MM | $77.51MM |
| Investing Cash Flow | $-332.25MM | $-352.62MM | $-221.11MM |
| Financing Cash Flow | $-3.89MM | $-1.63MM | $10.36MM |
| Earnings Per Share* | $0.56 | $0.56 | $-0.51 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.